Multidrug resistance 1 (MDR1) 3435C&gt;T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis

Muralidharan, Niveditha; Antony, Paul T; Jain, Vikramraj K; Mariaselvam, Christina Mary; Negi, Vir Singh

doi:10.1007/s00228-015-1885-0

Cited by 21 publications

(14 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 862 citations were collected from electronic databases, and, after excluding duplicates, screening titles and abstracts, and reading full articles, a total of 39 articles were included. 8,9,26-62 The study selection process is presented in Figure 1. The main characteristics of studies are summarized in Additional file 1: Table S1.…”

Section: Resultsmentioning

confidence: 99%

Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis

Huang

Fan

Qiu

et al. 2020

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Aims: We performed an updated meta-analysis to verify correlations between gene polymorphisms and adverse events in methotrexate (MTX)-treated rheumatoid arthritis (RA) patients. Then, we conducted a retrospective cohort study of Han Chinese in China. Methods: Relevant studies were collected from the PubMed database and the EMBASE database until December 2017. Pre-allele, dominant, recessive, codominant, and homozygotic models were applied. In addition, a retrospective cohort study enrolling 162 RA patients treated with MTX was conducted. Single nucleotide polymorphism (SNP) genotyping was analyzed by PCR and product sequencing. Results: A total of 39 studies were included in 20 meta-analyses; meta-analysis showed a significant association between MTX-related toxicity and 5,10-methylenetetrahydrofolate reductase (MTHFR) 677C>T(rs1801133) polymorphism in East Asian RA patients, and significant associations were observed between MTX-related toxicity and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) 347C>G (rs2372536), reduced folate carrier 1 (RFC-1) 80G>A (rs1051266), and adenosine triphosphate-binding cassette B1 (ABCB1) 3435C>T(rs1045642) polymorphisms in European RA patients but not in East Asian RA patients. Moreover, in our retrospective cohort study, ATIC 347C>G(rs2372536) and ABCB1 3435C>T(rs1045642) polymorphisms were not associated with MTX-related toxicity. However, a significant association was observed between MTX-related toxicity and RFC-1 80G>A (rs1051266) polymorphism in Chinese Han RA patients. Conclusion: Evidence-based results suggest that the MTHFR 677C>T(rs1801133), ATIC 347C>G(rs2372536), RFC-1 80G>A (rs1051266), ABCB1 3435C>T(rs1045642) polymorphisms are associated with MTX-related toxicity. Larger and more stringent study designs may provide more accurate findings for the effects of these SNPs on MTX-related toxicity, and larger sample-size studies of the Chinese Han population should be conducted for further validation.

show abstract

Section: Resultsmentioning

confidence: 99%

Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis

Huang

Fan

Qiu

et al. 2020

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…27 Genetic risk factors include polymorphisms in genes that regulate inflammatory pathways and genes that regulate drug metabolism. 29 For example, patients with AIGO have higher cytosolic concentrations of a protein that blocks apoptosis. 30 Apoptosis helps limit inflammation by causing cell lysis; without this intervention, cell cycles are longer, and cells can grow larger.…”

Section: Risk Factorsmentioning

confidence: 99%

Amlodipine-Induced Gingival Overgrowth: A Health Justice Issue

Portnoy¹,

Lee²,

McMullen³

et al. 2022

The Journal for Nurse Practitioners

View full text Add to dashboard Cite

“…The MDR-1 multidrug resistance gene, which is responsible for resistance to a wide variety of drugs in human cells, is potentially involved [10]. It is the result of a loss-of-function mutation in the P-pg glycoprotein gene involved in the transport of immunosuppressive drugs and chemotherapeutic agents [11]. In Graves' disease, elevated MDR-1 gene expression levels are associated with disease activ- TSHs valu (mUI/L) TSHs ity and treatment resistance [10].…”

Section: Commentsmentioning

confidence: 99%

Resistance to Anti-Thyroid Drugs in Graves’ Disease: Clinical-Biological Characteristics and Alternative Therapy in Tropical Area

Diack¹,

Ndiaye²,

Sène³

et al. 2020

OJEMD

View full text Add to dashboard Cite

Background: Resistance to anti-thyroid drugs (ATDs) is a rare entity recently described. We report two African observations in the treatment of Graves' disease. Case 1: A 19-year-old Senegalese woman presented on admission with thyrotoxicosis syndrome associated with diffuse goitre and Grave's orbitopathy. TSH levels were low (0.005 mIU/ml; N = 0.27-4.20) and fT4 elevated (60 pmol/L; N = 12-22]. Combination therapy with propranolol (40 mg/day) and carbimazole (starting dose of 45 mg/day and increased to 60 mg/day) was initiated. In view of the persistence of symptoms despite good therapeutic compliance, carbimazole was replaced by methimazole with an initial starting dose of 40 mg/day, followed by 60 mg/day. Despite the change in therapy, clinical symptoms of thyrotoxicosis persisted, and fT4 levels remained elevated. The patient was diagnosed with resistance to ATDs in Graves' disease. Total thyroidectomy following 10 days of preoperative preparation with 1% Lugol's solution was performed successfully. Case 2: A 22-year-old woman was referred for continued management of Graves' disease with elevated thyroid-stimulating hormone receptor antibody (TRAb) levels (34 UI/mL; N < 1.75). Treatment included propranolol (80 mg/day) and carbimazole at an unusual dose of 80 mg/day. Combined therapy was clinically and biologically ineffective, with an fT4 level of 100 pmol/L [N: 12-22]. Upon admission, methimazole (40 mg/day) followed by propylthiouracil (800 mg/day) replaced carbimazole. Despite good patient compliance, the patient's symptoms remained unaltered and fT4 levels elevated. A total robot thyroidectomy using the right axillary approach was performed successfully after 10 days of preoperative preparation, including prednisone (40 mg/day

show abstract

Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis

Abstract: MDR1 3435C>T gene polymorphism influences the clinical phenotype and adverse events to MTX in the South Indian cohort of patients with RA.

Cited by 21 publications

References 42 publications

Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis

Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis

Amlodipine-Induced Gingival Overgrowth: A Health Justice Issue

Resistance to Anti-Thyroid Drugs in Graves’ Disease: Clinical-Biological Characteristics and Alternative Therapy in Tropical Area

Contact Info

Product

Resources

About